Robert Barrow

Rob has served as our Chief Executive Officer since June 2021 and joined our Board of Directors in December 2021 overseeing the transformation of our organization and research and development pipeline. Under his leadership, the company has evolved into a leading biotechnology organization forging a new era of psychiatry by harnessing the full therapeutic potential of psychedelic medicine. Prior to joining the company, he led drug development and discovery at Usona Institute, served as Chief Operating Officer and Director at Olatec Therapeutics and has held advisory roles for numerous pharmaceutical companies.